Acelyrin announces layoffs, strategy shift after late-stage trial results for anti-inflammatory drug
Acelyrin, a California biotech, announced layoffs of 40 employees, a third of its workforce, following a pivot in priorities. Despite success in a late-stage trial for a skin disorder treatment, the drug didn't outperform competitors, leading to halted investment. The company will now focus on a thyroid eye disease treatment.
Reference News
Acelyrin, a California biotech, announced layoffs of 40 employees, a third of its workforce, following a pivot in priorities. Despite success in a late-stage trial for a skin disorder treatment, the drug didn't outperform competitors, leading to halted investment. The company will now focus on a thyroid eye disease treatment.
Acelyrin shifts focus from izokibep to lonigutamab for thyroid eye disease, suspending further investments in izokibep despite positive trial results. The company cuts 43 jobs, aiming to extend cash runway to 2027 for lonigutamab's Phase 3 trials, amidst strategic restructuring.